CRASH 3 Trial - Time Is Brain
- 9 years ago
#TimeIsBrain - randomise and treat urgently!
In this video Professor of Trauma Neurosurgery, Antonio Belli aims to emphasise the need to randomise and treat patients as early as possible using the wavier of consent (if your ethics committee has approved its use) in order to prevent further damage to the brain.
For more information or to follow the trial progress visit our:
Website: https://crash3.lshtm.ac.uk
Facebook: https://facebook.com/groups/CRASH3
LinkedIn: https://www.linkedin.com/grp/home?gid=8352506
The CRASH-3 trial is being conducted to assess the effect of tranexamic acid on the risk of death or disability in patients with Traumatic Brain Injury (TBI). TBI can cause bleeding in the brain. If left to continue, it can create pressure that can lead to further damage that will result in death or permanent disability. By conducting this trial we are collecting important evidence to help determine if tranexamic acid is an effective treatment for patients with TBI.
The CRASH-3 trial is inspired by the results of the CRASH-2 trial. The CRASH-2 trial showed that tranexamic acid, an affordable and heat stable drug, reduced death due to bleeding and had the most beneficial effect when administered as soon as possible after injury.
In this video Professor of Trauma Neurosurgery, Antonio Belli aims to emphasise the need to randomise and treat patients as early as possible using the wavier of consent (if your ethics committee has approved its use) in order to prevent further damage to the brain.
For more information or to follow the trial progress visit our:
Website: https://crash3.lshtm.ac.uk
Facebook: https://facebook.com/groups/CRASH3
LinkedIn: https://www.linkedin.com/grp/home?gid=8352506
The CRASH-3 trial is being conducted to assess the effect of tranexamic acid on the risk of death or disability in patients with Traumatic Brain Injury (TBI). TBI can cause bleeding in the brain. If left to continue, it can create pressure that can lead to further damage that will result in death or permanent disability. By conducting this trial we are collecting important evidence to help determine if tranexamic acid is an effective treatment for patients with TBI.
The CRASH-3 trial is inspired by the results of the CRASH-2 trial. The CRASH-2 trial showed that tranexamic acid, an affordable and heat stable drug, reduced death due to bleeding and had the most beneficial effect when administered as soon as possible after injury.